CMT Research Foundation and Nanite Inc. Announce Partnership to Enhance Therapeutic Efficacy of Antisense Oligonucleotides in CMT1A
As part of the partnership agreement, Nanite will design delivery vehicles for genetic medicines to Schwann cells via PNPs, an emerging technology for drug delivery to hard-to-hit targets.
- As part of the partnership agreement, Nanite will design delivery vehicles for genetic medicines to Schwann cells via PNPs, an emerging technology for drug delivery to hard-to-hit targets.
- This makes Schwann cells the primary target of genetic therapies in most cases of CMT.
- The safe delivery of medicines to the Schwann cells of patients with CMT1A, would mark a dramatic step forward in the potential of gene therapies for CMT disease.
- The CMT Research Foundation (CMTRF) is focused solely on delivering treatments and cures for CMT.